Document G6J0jkYrdypBVeKGo0nOzLjnV

valuation of existing literature should be started soon. Dr. Richard Kociba recommended that the panel invite scientists with opposing viewpoints to the symposium so that issues can be openly discussed and a balanced view can be presented to the scientific community at larg . 3.0 Polychlorinated Biphenyls Mr. David Zoll reviewed Tab 1 of the work book (SPAG-ll-A), stating that the court ruling in the case of EDF v. EPA has far reaching implications for th industry. He described the May 1, 1981 industry-wide seminar which will explain the implications of the court-ruling for the chemical industry and the necessity for broad-based participation in the "incidental generation" and "totally enclosed uses" surveys. SPAG approved Phase I of the PCS program under the Division of Special Programs. Phase I will include conducting two surveys, analyzing the data and participation in formal rulemaking. SPAG will review the orogram at the end of Phase I and will decide whether Phase II, if necessary, should be continued under Special Programs or should be sent back to Chemical Regulations Advisory Committee. The Phase II may include litigation. 4.0 Ketones Program Dr. Donald Heywood reviewed Tab 3 of the work book. The program panel will evalute the need for developing toxicology information on acetone, methyl isobutyl ketone, methyl ethyl ketone, methyl isoarayl ketone, mesityl oxide, isophorone, and cyclohexanone. SPAG endorsed Dr. Heywood's suggestion that in addition to the panel's response, each member company should respond to the Federal Register notices of test rule development. Dr. Heywood sought SPAG's guidance in two soecific areas: (i) obtaining relevant information from CUT on methyl ethyl ketone and (ii) establishing early dialogue with EPA regarding the TSCA section 4(a) anticipated rule. 4.1 CUT Study on MEK -- Dr. Heywood informed SPAG that CUT has cancelled its chronic inhalation study on methyl ethyl ketone, a chemical that is a TSCA Section 4(a) candidate and which is of concern to the panel. Neither he nor other panel members w re 3 CMA121926